Filter results
10/05/2023
ROVI reached 201.9 million euros of revenue in the first post-pandemic quarter
25/04/2023
ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
The objective of the new three-monthly formulation is to reach bioequivalence in the plasma levels of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg
12/04/2023
The objective is to help improve society’s mental health and take advantage of the opportunities the new technologies offer to enhance the quality of life and the care that people receive.
27/03/2023
The group is collaborating with ReTree to recover an area of the Sierra del Rincón through reforestation with native tree species
21/03/2023
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.
21/02/2023
ROVI reports operating revenue growth of 26% and EBITDA growth of 37%
16/02/2023
ROVI has now filed the final responses to the Complete Response Letter received from the United States Food and Drug Administration (FDA) in the third quarter of 2022
06/02/2023
The Minister, Alexandru Rafila, was accompanied by the Director of Cabinet of the Romanian Ministry of Health and the Romanian Ambassador to Spain.